Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Launched by NICOLE BACA · Feb 17, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to identify early signs of cancer in children with a condition called Neurofibromatosis Type 1 (NF-1). The researchers are using special whole-body MRI scans combined with advanced computer technology (artificial intelligence) to see how well these methods work over time. They are studying 15 children aged 5 to 17 at Cedars-Sinai Medical Center to find out if the scans can reliably detect changes that might indicate the presence of pre-malignant lesions, which are growths that could potentially become cancerous.

To participate, children must be between 5 and 17 years old and have a confirmed diagnosis of NF-1, including those with a specific type of NF-1 called mosaic or segmental NF-1. However, children who need sedation for the scans, have certain implants, or struggle with being in enclosed spaces cannot join the study. Participants will undergo MRI scans at the beginning of the study and again after 12 months, allowing researchers to track any changes. This trial is an important step in finding better ways to monitor and manage NF-1 in young patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Between the ages of 5 and \<18 years at the start of study. If subject will turn 18 during the study, they will be allowed to enroll.
• • Clinically or molecularly confirmed diagnosis of NF-1. Subjects with mosaic/segmental NF-1 also qualify for the study.
• Exclusion Criteria:
• • Requiring sedation for imaging.
• • Implants and/or Devices: Mechanical, magnetic or electrical activated implants; Ferromagnetic implants and foreign bodies
• • Claustrophobia, problems being in enclosed spaces, or inability to lie facing upwards.
• • Allergy to animal dander or animal-instigated asthma.